The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Recruiting now

Safety and Effectiveness Evaluation of the COLO-BT as an Alternative Treatment to the Ileostomy

Not phased · randomised · 256 people · 3 sites in United States · Recruiting now

August 11, 2026
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Phase 1 · 914 people · 48 sites in 10 countries · Recruiting now

August 11, 2026
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2

Phase 2 · 111 people · 54 sites in 11 countries · Recruiting now

August 11, 2026
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Phase 2 · 50 people · 1 site in United States · Recruiting now

August 11, 2026
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Phase 1 · 300 people · 38 sites in 5 countries · Recruiting now

August 11, 2026
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 2 · 500 people · 165 sites in 19 countries · Recruiting now

August 11, 2026
Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

Phase 2 · 34 people · 1 site in China · Recruiting now

August 11, 2026
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Phase 2 · 167 people · 4 sites in United Kingdom · Recruiting now

August 11, 2026
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

Phase 1 · 146 people · 10 sites in 3 countries · Recruiting now

August 11, 2026
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

Phase 2 · 178 people · 1 site in China · Recruiting now

August 11, 2026